Human papillomavirus infection among Uyghur women with cervical intraepithelial neoplasia in Xinjiang area

Objective: To obtain the baseline data of Uyghur women for human papillomavirus (HPV) vaccination in Xinjiang. Materials and Methods: The authors analyzed the infection and distribution characteristics of HPV genotypes in genital tracts among Uyghur women with cervical intraepithelial neoplasia (CIN) in Urumqi of Xinjiang.A total of 1,431 eligible cases involved in this trial. All cervical samples from these patients were detected for HPV genotype. Results: High-risk HPV was identified in 24.7% of 979 histologically confirmed normal samples and 89.2% of 452 samples with CIN (p < 0.05). The prevalence of one single high-risk type, low-risk type, and multiple HPV types were 74.6%, 10.4%, and 4.2%, respectively.A single high risk HPV infection progressively increased with the severity of cervical lesions significantly (χ2= 31.53, p < 0.01). While interestingly multiple infection and single low risk HPV infection were decreased with the severity of cervical lesions, and there was significant difference (χ2= 6.44, p < 0.05; χ2= 4.85, p < 0.05). The major prevalent high-risk HPV genotypes in 346 samples of CIN II-III were HPV-16, -58, -31, -33, -68,-18,-45, and -39. The comparison of HPV genotype distributions between normal cytology and CIN II-III was analyzed. The estimated risks for progression from viral infection to CIN II-III was highest in HPV- 33 (prevalence ratio (PR), 2.62), followed by HPV-31 (2.27), HPV-16 (1.92), HPV-58 (1.62), HPV-18 (1.51), HPV-68 (1.05), and HPV-39 (1.05), suggesting that the six genotypes of HPV-31, -16, -58, -18, -68, and -39 (PR > 1) are higher-risk HPV types in Uyghur women with CIN in Urumqi of Xinjiang. There was no association between multiple infection and cervical lesion progression (0.31, PR < 1). Conclusion: Except for the common HPV-16, -58, -31, -33, -18 in Xinjiang, HPV-68 and HPV-39 may be the oncogenic subtypes to Uyghur female with CIN in Xinjiang. Distinguishing these HPV subtypes may have implications for future cervical screening strategies and vaccine implementation. Multiple infections were not association with an increased risk of high-grade cervical neoplasia.

Cervical intraepithelial neoplasia; Human papillomavirus; Genotypes; Infection characteristics; Uyghur.

[1] Parkin M., Bray F., Ferlay J., Pisani P: “Global cancer statistics, 2002”. CA Cancer J, Clin., 2005, 55, 74.

[2] Muñoz N., Bosch F.X., de Sanjosé S., Herrero R., Castellsagué X., Shah K.V., et al.: “Epidemiologic classification of human papillo-mavirus types associated with cervical cancer”. N. Engl. J. Med., 2003, 348, 518.

[3] Bhatla N., Lal N., Bao Y.P., Ng T., Qiao Y.L.: “A meta-analysis of human papillomavirus type-distribution in women from South Asia: Implications for vaccination”. Vaccine, 2008, 26, 2811.

[4] Smith J.S., Lindsay L., Hoots B., Keys J., Franceschi S., Winer R., et al.: “Human papillomavirus type distribution in invasive cervical cancer and high-grade cervical lesions: a meta-analysis update”. Int. J. Cancer, 2007, 121, 621.

[5] Wright T.C. Jr., Schiffman M., Solomon D., Cox J.T., Garcia F., Goldie S., et al.: “Interim guidance for the use of human pappillo-mavirus DNA testing as an adjunct to cervical cytology for screen-ing”. Obstet. Gynecol., 2004, 103, 304.

[6] Koutsky LA,Harper DM.Chapter 13:Current findings from prophy-lactic HPV vaccine trials.Vaccine 2006;24(Suppl 3):S114-21

[7] Paavonen J., Naud P., Salmerón J., Wheeler C.M., Chow S.N., Apter D., et al.: “Efficacy of human papillomavirus (HPV)-16/18 AS04-ad-juvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women”. Lancet, 2009, 374, 301.

[8] Clifford G.M.,Smith J.S., Aguado T., Franceschi S.: “Comparision of HPV type distribution in high-grade cervical lesions and cervical cancer:a meta-analysis”. Br. J. Cancer, 2003, 89, 101.

[9] Bao Y.P., Li N., Smith J.S., Qiao Y.L.: “Human papillomavirus type distribution in women from Asia: a meta-analysis”. Int. J. Gynecol. Cancer, 2008, 18, 71.

[10] Tjalma W.A., Fiander A., Reich O., Powell N., Nowakowski A.M., Kirschner B., Koiss R., et al.: “Differences in human papillomavirus type distribution in high-grade cervical intraepithelial neoplasia and invasive cervical cancer in Europe”. Int. J. Cancer, 2012, 132, 854.

[11] Chen W., Zhang X., Molijn A., Jenkins D., Shi J.F., Quint W., Schmidt J.E., et al.: “Human papillomavirus type-distribution in cervical cancer in China: the importance of HPV 16 and 18”. Cancer Causes Control, 2009, 20, 1705.

[12] Sandri M.T., Riggio D., Salvatici M., Passerini R., Zorzino L., Boveri S., Radice D., et al.: “Typing of human papillomavirus in women with cervical lesions: Prevalence and distribution of different genotypes”. J. Med. Virol., 2009, 81, 271.

[13] Bosch F.X., Lorincz A., Muñoz N., Meijer C.J., Shah K.V.: “The casual relation between human papillomavirus and cervical cancer”. J. Clin. Pathol., 2002, 55, 244.

[14] Spinillo A., Bello B.D., Gardella B., Roccio M., Dacco M.D., Sinili E.M.: “Multiple human papillomavirus infection and high grade cervical intraepithelial neoplasia among women with cytological diagnosis of atypical squamous cells of undetermined significance or low grade squamous intraepithelial lesions”. Gynecol. Oncol., 2009, 113, 115.

[15] Herrero R., Castle P.E., Schiffman M., Bratti M.C., Hildesheim A., Morales J., et al.: “Epidemiologic profile of type-specific human papillomavirus infection and cervical neoplasia in Guanacaste, Costa Rica”. J. Infect. Dis., 2005, 191, 1796.

[16] Sandri M.T., Riggio D., Salvatici M., Passerini R., Zorzino L., Boveri S., et al.: “Typing of human papillomavirus in women with cervical lesions: Prevalence and distribution of different genotypes”. J. Med. Virol., 2009, 81, 271.

[17] Cuschieri K.S., Cubie H.A., Whitley M.W., Seagar A.L., Arends M.J., Moore C., et al.: “Multiple high risk HPV infections are common in cervical neoplasia and young women in a cervical screening population” J. Clin. Pathol., 2004, 57, 68.

[18] Clifford G.M., Gallus S., Herrero R., Muñoz N., Snijders P.J., Vaccarella S., et al.: “Worldwide distribution of human papillomavirus types in cytologically normal women in the International Agency for Research on Cancer HPV prevalence surveys: a pooled analysis”. Lancet, 2005, 366, 991.

[19] Neerja B., Lalit D., Patro A.R., Kumar P., Pati S.K., Alka K., Gulati A., et al.: “Human papillomavirus-type distribution in women with and without cervical neoplasia in north India”. Int J Gynecol. Pathol., 2008, 27, 426.

[20] Khan M.J., Castle P.E., Lorincz A.T., Wacholder S., Sherman M., Scott D.R. et al.: “The elevated 10-year risk of cervical precancer and cancer in women with human papillomavirus (HPV) type 16 or

18 and the possible utility of type-specific HPV testing in clinical practice”. J. Natl. Cancer Inst., 2005, 97, 1072.

[21] Castle P.E., Sadorra M., Garcia F., Holladay E.B., Kornegay J.: “Pilot study of a commercialized human pa.pillomavirus (HPV) genotyping assay: comparison of HPV risk group to cytology and histology”. J. Clin. Microbiol., 2006, 44, 3915.

[22] Castle P.E., Schiffman M., Wheeler C.M., Solomon D.: “Evidence for frequent regression of cervical intraepithelial neoplasia-grade 2”. Obstet. Gynecol., 2009, 113, 18.